Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking.
Bakkerus L, Buffart LM, Buffart TE, Meyer YM, Zonderhuis BM, Haasbeek CJA, Versteeg KS, Loosveld OJL, de Groot JWB, Hendriks MP, Verhoef C, Verheul HMW, Gootjes EC. Bakkerus L, et al. Among authors: buffart te. J Natl Compr Canc Netw. 2023 Oct;21(10):1059-1066.e5. doi: 10.6004/jnccn.2023.7050. J Natl Compr Canc Netw. 2023. PMID: 37856212 Clinical Trial.
Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer.
Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW. Neerincx M, et al. Among authors: buffart te. PLoS One. 2018 Aug 3;13(8):e0201809. doi: 10.1371/journal.pone.0201809. eCollection 2018. PLoS One. 2018. PMID: 30075027 Free PMC article.
Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.
Gootjes EC, van der Stok EP, Buffart TE, Bakkerus L, Labots M, Zonderhuis BM, Tuynman JB, Meijerink MR, van de Ven PM, Haasbeek CJA, Ten Tije AJ, de Groot JB, Hendriks MP, van Meerten E, Nuyttens JJME, Grunhagen DJ, Verhoef C, Verheul HMW; ORCHESTRA study group. Gootjes EC, et al. Among authors: buffart te. Oncologist. 2020 Aug;25(8):e1195-e1201. doi: 10.1634/theoncologist.2019-0693. Epub 2020 Jun 16. Oncologist. 2020. PMID: 32490570 Free PMC article. Clinical Trial.
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AGJ, Kok NFM, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJA, Verheul HMW, Kruijff S, de Groot DJA, Witkamp AJ, van Grevenstein WMU, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJA, van 't Erve I, Snaebjornsson P, Hemmer PHJ, Dijkgraaf MGW, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group. Rovers KP, et al. Among authors: buffart te. JAMA Surg. 2021 Aug 1;156(8):710-720. doi: 10.1001/jamasurg.2021.1642. JAMA Surg. 2021. PMID: 34009291 Free PMC article. Clinical Trial.
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, Lemmens VE, Koopman M, Bol GM; EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group. van Nassau SC, et al. Among authors: buffart te. JAMA Netw Open. 2021 Sep 1;4(9):e2124766. doi: 10.1001/jamanetworkopen.2021.24766. JAMA Netw Open. 2021. PMID: 34505885 Free PMC article.
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K, Schaap DP, Voogt ELK, Buffart TE, Verheul HMW, de Groot JWB, Verhoef C, Melenhorst J, Roodhart JML, de Wilt JHW, van Westreenen HL, Aalbers AGJ, van 't Veer M, Marijnen CAM, Vincent J, Simkens LHJ, Peters NAJB, Berbée M, Werter IM, Snaebjornsson P, Peulen HMU, van Lijnschoten IG, Roef MJ, Nieuwenhuijzen GAP, Bloemen JG, Willems JMWE, Creemers GJM, Nederend J, Rutten HJT, Burger JWA. van den Berg K, et al. Among authors: buffart te. BMC Cancer. 2022 Sep 6;22(1):957. doi: 10.1186/s12885-022-09947-w. BMC Cancer. 2022. PMID: 36068495 Free PMC article.
61 results